Title (en)

DRUG-CARRIER COMPLEXES AND METHODS OF USE THEREOF

Title (de)

ARZNEIMITTELTRÄGER KOMPLEXE UND IHRE VERFAHREN UND ANWENDUNG

Title (fr)

COMPLEXES VECTEURS DE MEDICAMENT ET TECHNIQUE D'UTILISATION DE CEUX-CI

Publication

EP 1206285 A2 20020522 (EN)

Application

EP 00955415 A 20000809

Priority

- US 0021762 W 20000809
- US 14791999 P 19990809

Abstract (en)

[origin: WO0110468A2] Drug-carrier complexes, drug carriers, pharmaceutical formulations, methods of delivery drugs to an organism or tissue culture, methods of increasing the solubility of a substance, targeted carriers, drug delivery systems and implants are described. The compositions and methods of the invention include forming complexes having reversible associations between nucleotides and drugs. The compositions and methods of the invention can be employed to target drugs to cells, organisms or combinations of cells to treat and to study the underlying mechanisms of diseases, and to test drug candidates.

IPC 1-7

A61K 47/48

IPC 8 full level

A61K 9/06 (2006.01); **A61K 9/14** (2006.01); **A61K 9/50** (2006.01); **A61K 9/70** (2006.01); **A61K 31/282** (2006.01); **A61K 31/704** (2006.01); **A61K 31/7088** (2006.01); **A61K 31/7105** (2006.01); **A61K 33/24** (2006.01); **A61K 38/00** (2006.01); **A61K 45/00** (2006.01); **A61K 47/48** (2006.01); **A61K 48/00** (2006.01); **A61K 49/00** (2006.01); **A61K 49/04** (2006.01); **A61K 51/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/12** (2006.01); **A61P 33/02** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C12N 15/09** (2006.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01); **G01N 33/58** (2006.01)

CPC (source: EP)

A61K 47/549 (2017.07); **A61P 31/04** (2017.12); **A61P 31/12** (2017.12); **A61P 33/02** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 0110468A2

Citation (examination)

- GB 1440626 A 19760623 - FARMACEUTICI ITALIA
- HUFF; KREUZER: "Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 256, 1990, pages 20496 - 20505
- PULLMAN: "Sequence specificty in the binding of anti-tumour anthracyclines to DNA: a success of theory", ANTI-CANCER DRGU DESIGN, vol. 7, 1991, pages 95 - 105
- YANG; WANG: "Structural studies of atom-specific anticancer drugs acting on DNA", PHARMACOLOGY AND THERAPEUTICS, vol. 83, 1999, pages 181 - 215
- ZIEGLER ET AL: "induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence", JOURNAL OF THE NATIONAL CERCER INSTITUTE, vol. 89, 1997, pages 1027 - 1036, XP002080869, DOI: doi:10.1093/jnci/89.14.1027
- LIPSCOMB ET AL: "Water ring structure at DNA interfaces: hydration and dynamics of DNA-anthracycline conplexes", BIOCHEMISTRY, vol. 33, 1994, pages 3649 - 3659
- HERSCHLAG ET AL: "An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis", THE EMBO JOURNAL, vol. 13, 1994, pages 2913 - 2924, XP000567895

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0110468 A2 20010215; **WO 0110468 A3 20020117**; AU 6762600 A 20010305; EP 1206285 A2 20020522; JP 2003506417 A 20030218; JP 2011231122 A 20111117; JP 4813712 B2 20111109

DOCDB simple family (application)

US 0021762 W 20000809; AU 6762600 A 20000809; EP 00955415 A 20000809; JP 2001514984 A 20000809; JP 2011155154 A 20110713